Regulations last checked for updates: Nov 22, 2026

Title 21 - Food and Drugs last revised: Nov 12, 2026
§ 878.1830 - Software-aided adjunctive diagnostic device for use by physicians on lesions suspicious for skin cancer.

(a) Identification. A software-aided adjunctive diagnostic device for use by physicians on lesions suspicious for skin cancer is a prescription device that uses a software algorithm to analyze optical or other physical properties of a skin lesion and returns a classification of the skin lesion. The device is intended for use by a physician not trained in the clinical diagnosis and management of skin cancer as an adjunctive second-read device following identification of a suspicious skin lesion. It is not for use as a standalone diagnostic and is not for use to confirm a clinical diagnosis.

(b) Classification. Class II (special controls). The special controls for this device are:

(1) Data obtained from premarket clinical performance validation testing and postmarket surveillance acquired under anticipated conditions of use must demonstrate that the device performs as intended in the intended patient population, unless FDA determines based on the totality of the information provided for premarket review that data from postmarket surveillance is not required.

(i) Data must demonstrate superior accuracy of device-aided users' diagnostic characterization of the indicated lesions compared to the accuracy of unaided users.

(ii) Clinical testing must evaluate patients across a range of skin phototypes, risk factors, and anatomic areas that represents the intended use population.

(iii) Standalone device performance testing must demonstrate the accuracy of the device output relative to ground truth, including the following:

(A) Testing must demonstrate at least 90 percent sensitivity of the device output for lesions with high metastatic potential, or an alternative clinical consideration must be provided to justify lower sensitivity. Clinical justification must be provided for the reported specificity.

(B) Lesions must be selected by representative users and include a justified quantity and range of mimic lesions per diagnosis.

(C) Justification must be provided for the determination of ground truth.

(D) Testing must include a representative range of individuals with diverse risk factors (including age, body site, skin phototype, and other clinical factors), and analysis of standalone performance must include subgroup analysis by relevant risk factors.

(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including compatibility testing of the device software with specific signal or image acquisition hardware. Testing must include a description of compatible hardware and processes, pre-specified compatibility testing protocols, and dataset(s).

(3) Performance testing must demonstrate device precision, including repeatability and reproducibility of device performance, across operators and challenging use conditions.

(4) Performance testing must demonstrate the electrical safety, mechanical safety, thermal safety, and electromagnetic compatibility of any electrical components of the device.

(5) Performance testing must validate reprocessing instructions for reusable components of the device.

(6) The patient-contacting components of the device must be demonstrated to be biocompatible.

(7) Software verification, validation, and hazard analysis must be performed.

(8) Human factors assessment must demonstrate that the device can be safely and correctly used by intended users.

(9) Labeling must include:

(i) A summary of standalone and clinical performance testing conducted with the device that describes performance measures, including sensitivity and specificity, and statistical confidence intervals, as well as performance of the device for all clinically relevant subgroups within the intended use population;

(ii) A description of the patient population that was used in development or training of the device algorithm;

(iii) Device limitations or subpopulations for which the device may not perform as expected or for whom the device has not been validated;

(iv) Information for interpretation of the device outputs detailing the risks associated with misinterpretation of the device outputs;

(v) Warnings to avoid unsafe exposure to any energy-emitting components of the device, e.g., excluding lesions close to the eye;

(vi) A statement that the device is not intended for use as a standalone diagnostic; and

(vii) Instructions for device maintenance and validated methods and instructions for reprocessing of any reusable components.

[91 FR 68467, Oct. 30, 2026]
authority: 21 U.S.C. 351,360,360c,360e,360j,360
source: 53 FR 23872, June 24, 1988, unless otherwise noted.
cite as: 21 CFR 878.1830